Cancer Clinical Trials Information Platform in Hong Kong


  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials


Cancer Site


*in alphabetical order (Last updated on 29/6/2022)


Prostate Cancer

Institution Study Title  
CUHK Randomized phase II study of combination androgen deprivation therapy (ADT) and radiotherapy in high risk prostate cancer: Stereotactic body Radiotherapy vs conventionAl IMRT to prostate and pelvic nodes (SRAM study) Click for Details
QMH A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX) Contact:
Ms. Irene Koo
2255 6220
QMH A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) Contact:
Ms.Carmen Chiu
22554915
CUHK A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX) Click for Details
CUHK PSMA-PET guided Stereotactic Ablative Body Radiotherapy for Oligometastasisin metastatic castration-resistant prostate cancer (mCRPC) with progression on Enzalutamide (PMSABR study) Click for Details
CUHK A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) characterised by PTEN deficiency (CAPItello-281) Click for Details
QMH TrueNTH Global Registry‐ Prostate Cancer Outcomes Contact:
Ms. Irene Koo
2255 6220


For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.